Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 35

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 35
---
 a going concern. Should it become evident in the future that there are no realistic
financing options available to us which are actionable before our cash resources run out, then we will no longer be a going concern. In
such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements
would be prepared on a liquidation basis and assets would be stated at net realizable value and all liabilities would be accelerated to
current liabilities.

We believe there are adequate
options and time available to secure additional financing for the Company and after considering the uncertainties, we considered it appropriate
to continue to adopt the going concern basis in preparing the financial information.

Our ability to continue as
a going concern is dependent upon our ability to obtain additional capital and/or dispose of assets, for which there can be no assurance
we will be able to do on a timely basis, on favorable terms or at all.

Our operations are in early-stage development with no sources of recurring revenue and there is no assurance that we will successfully develop and license our product candidates or ever become profitable.

We are at a relatively early
stage of our commercial development. To date, we have generated a minimal amount of revenue from our product candidates. Our ability to
generate revenue and become and remain profitable depends, in part, on our ability to successfully find a licensing partner for our product
candidates, or other product candidates we may in-license or acquire, and have such candidates successfully commercialized. Our current
strategy is, once proof-of-concept of our product candidates has been established, to generate revenue via a partner, thereby earning
royalty and/or milestone income; however, this is not expected to materialize in the foreseeable future, and there can be no guarantee
we will be able to find a licensing partner for our product candidates. Even if our product candidates were to successfully achieve regulatory
approval, we do not know when any of the product candidates will generate revenue, if at all. Our ability to generate revenue from our
product candidates also depends on a number of additional factors, including our ability, and the ability of any licensing partners, to:

| • | successfully complete development activities; |

| • | complete and submit new drug applications to the European Medicines Agency, or the EMA, the Medicines                                    
 and Healthcare Products Regulatory Agency in the United Kingdom, or the MHRA, the FDA, and any other foreign regulatory authorities, and 
 obtain regulatory approval for products for which there is